ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 4 syntheses or guidelines pooled it, 354 citations in OpenAlex.
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Guideline
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.ESMO open · 2022Guideline
- European Myeloma Network guidelines for the management of multiple myeloma-related complications.Haematologica · 2015Guideline
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Haematologica · 2014Guideline
- Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.Blood advances · 2021Trial
- Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Trial
- Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.Haematologica · 2015Trial
- Exercise for myeloma patients with bone disease: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series.British dental journal · 2026Article
- The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- Management of bone health in cancer survivorship: a systematic review of clinical guidelines.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Identification of Needs of Patients with Multiple Myeloma: A Questionnaire-Based Study in Israeli Patients.Acta haematologica · 2026Article
- Clinical and laboratory characteristics and management in patients diagnosed with multiple myeloma: real-world cohort in a Peruvian referral clinic.Ecancermedicalscience · 2026Article
- RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.World journal of surgical oncology · 2025Article
- Multiple Myeloma Presenting as Cauda Equina Syndrome: A Rare and Early Spinal Manifestation.Journal of orthopaedic case reports · 2025Article
- Review
- LY6E as a new prognostic biomarker of multiple myeloma-related bone disease.Scientific reports · 2025Article
- Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi journal of biological sciences · 2024Review
- Transoral balloon kyphoplasty in a myeloma patient with painful osseous destruction of the corpus vertebrae axis.Journal of surgical case reports · 2024Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 3 countries.
Funding
Abstract
purposeThe aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. METHODOLOGY: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. RECOMMENDATIONS: Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.